3-iodobenzylguanidine has been researched along with Disease Exacerbation in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (12.50) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 22 (55.00) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Braunstein, SE; DuBois, SG; Fishel Ben Kenan, R; Haas-Kogan, DA; Hawkins, RA; Matthay, KK; Polishchuk, AL | 1 |
| Borges-Neto, S; Kane, A; Morse, MA; Thorpe, MP; Wong, T; Zhu, J | 1 |
| Daida, K; Funayama, M; Hattori, N; Ishiguro, M; Ishiguro, Y; Li, Y; Nishioka, K; Oyama, G; Saiki, S; Yoshino, H | 1 |
| Azevedo Coutinho, MDC; Cantinho, G; Conceição, I; Cortez-Dias, N; Francisco, AR; Guimarães, T; Lima da Silva, G; Nobre Menezes, M; Pinto, FJ; Plácido, R | 1 |
| Kim, JS; Lee, JE; Lee, KS; Oh, YS; Ryu, DW; Yoo, IR | 1 |
| Alexander, N; Baruchel, S; Batra, V; Irwin, MS; Marrano, P; Martinez, D; Naranjo, A; Thorner, P; Van Ryn, C; Zhang, L | 1 |
| Echebarria, A; Genolla, J; Llorens, V; Lopez-Almaraz, R; Minguez, P; Rodriguez, T | 1 |
| Jacobson, AF; Kasama, S; Matsui, T; Matsuo, S; Momose, M; Nakajima, K; Nakata, T; Travin, MI; Yamada, T; Yamashina, S | 1 |
| Bokhari, S; Castaño, A; Maurer, MS; Shahzad, R | 1 |
| Fukuoka, M; Higuchi, T; Inaki, A; Ito, YM; Jinguji, M; Kayano, D; Kinuya, S; Nakajo, M; Okamoto, S; Oriuchi, N; Shiga, T; Tomiyama, Y; Toratani, A; Wakabayashi, H; Yoshinaga, K | 1 |
| Abe, K; Baba, S; Higo, T; Honda, H; Isoda, T; Kamitani, T; Kawanami, S; Kitamura, Y; Maruoka, Y; Nagao, M; Sunagawa, K; Yamasaki, Y; Yonezawa, M | 1 |
| Buteau, FA; Makis, W; McCann, K; McEwan, AJ | 1 |
| Cerqueira, MD; Gerson, M; Jacobson, AF; Narula, J; Thomas, GS | 1 |
| Doral, MY; DuBois, SG; Matthay, KK; Villablanca, JG; Yanik, GA; Zhou, MJ | 1 |
| Berukstis, A; Burneikaite, G; Gargalskaite, U; Laucevicius, A; Miglinas, M; Misonis, N; Vajauskas, D; Zakarkaite, D | 1 |
| Iikuni, Y; Ito, H; Kang, Y; Morimatsu, A; Murakami, T; Shirata, A; Ugawa, Y; Yamada, A; Yamane, K | 1 |
| Iida, H; Kobayashi, F; Miwa, M; Nagasaka, K; Nagasaka, T; Nakamura, Y; Shindo, K; Shiozawa, Z; Togashi, S; Watanabe, H | 1 |
| Arabia, G; Bagnato, A; Cascini, GL; Cipullo, S; Condino, F; Messina, D; Morelli, M; Morgante, L; Nicoletti, G; Novellino, F; Paglionico, S; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Matsuda, H; Mizumura, S; Waragai, M; Yamada, T | 1 |
| Bombardieri, E; Lucignani, G | 1 |
| Alhashimi, DM; Buscombe, JR; Caplin, ME; Navalkissoor, S; Quigley, AM | 1 |
| Hama, T; Hirayama, M; Hori, N; Nakamura, T; Sobue, G; Takamori, M; Uchida, K; Yamashita, F | 1 |
| Agostini, D; Cerqueira, MD; Chandna, H; Jacobson, AF; Lopez, VA; Narula, J; Senior, R; Thomas, GS; Weiland, F; Wong, ND | 1 |
| Amanullah, A; Ananthasubramaniam, K; Caldwell, JH; Clements, IP; Gerson, MC; Henzlova, MJ; Jacobson, AF | 1 |
| Hage, FG; Iskandrian, AE | 1 |
| Chung, SW; Kim, JS; Kim, YD; Lee, KS; Oh, YS | 1 |
| Casaretti, L; Cecere, M; Cuocolo, A; Dellegrottaglie, S; Gargiulo, P; Marciano, C; Musella, F; Paolillo, S; Parente, A; Perrone-Filardi, P; Pirozzi, E; Savarese, G | 1 |
| Duque, KS; Ovadia, M | 1 |
| Bourgoun, M; Jacobson, AF; Narula, J; Shah, AM; Solomon, SD | 1 |
| Hoefnagel, CA; Muller, M; Taal, BG; Valdes Olmos, RA; Zuetenhorst, JM | 1 |
| Abe, S; Arao, T; Inoue, S; Kubota, I; Sata, M; Shibata, Y; Takabatake, N; Takeishi, Y | 1 |
| Akatsu, H; Fujita, M; Hashimoto, M; Ho, G; Masliah, E; Mizuno, H; Nakai, M; Waragai, M; Wei, J; Yokochi, F | 1 |
| Fukuyama, H; Kawanishi, T; Mitake, S; Oguri, T; Tachibana, N | 1 |
| Barlier, A; Colavolpe, C; De Micco, C; Henry, JF; Morange, I; Mundler, O; Niccoli-Sire, P; Palazzo, FF; Sebag, F; Taïeb, D; Tessonnier, L | 1 |
| Hutchinson, RJ; Shapiro, B; Shulkin, BL; Sisson, JC; Zempel, S | 1 |
| Diociaiuti, L; Mastrangelo, S; Riccardi, R; Rufini, V; Tornesello, A; Troncone, L | 1 |
| Fukumoto, Y; Kuroda, Y; Ohkoshi, N; Yoshida, M | 1 |
| Iwasa, K; Nakajima, K; Tada, A; Takamori, M; Taki, J; Yoshikawa, H | 1 |
| Orimo, S; Ozawa, E; Tanaka, H; Tsuchiya, K; Yasui, H | 1 |
| de Groot, AC; de Milliano, PA; Lie, KI; Tijssen, JG; van Eck-Smit, BL; van Zwieten, PA | 1 |
5 review(s) available for 3-iodobenzylguanidine and Disease Exacerbation
| Article | Year |
|---|---|
A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Biomarkers; Chi-Square Distribution; Databases as Topic; Disease Progression; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radionuclide Imaging; Radiopharmaceuticals; Risk Factors; ROC Curve; Stroke Volume; Sympathetic Nervous System; Time Factors; Ventricular Function, Left | 2013 |
Nuclear imaging modalities for cardiac amyloidosis.
Topics: 3-Iodobenzylguanidine; Amyloidosis; Cardiomyopathies; Diphosphonates; Disease Progression; Heart Diseases; Humans; Iodine Radioisotopes; Organotechnetium Compounds; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals; Technetium; Technetium Tc 99m Pyrophosphate; Tomography, Emission-Computed, Single-Photon | 2014 |
Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Animals; Disease Progression; Humans; Molecular Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Radionuclide Imaging | 2009 |
Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal.
Topics: 3-Iodobenzylguanidine; Disease Progression; Heart Failure; Humans; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Risk Assessment; Sympathetic Nervous System | 2011 |
The potential utility of (123)I-mIBG in atrial fibrillation and in the electrophysiology laboratory.
Topics: 3-Iodobenzylguanidine; Atrial Fibrillation; Catheter Ablation; Cost-Benefit Analysis; Disease Progression; Female; Humans; Male; Patient Selection; Prevalence; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome; United States | 2012 |
3 trial(s) available for 3-iodobenzylguanidine and Disease Exacerbation
| Article | Year |
|---|---|
Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Interferon alpha-2; Interferon-alpha; Intestinal Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Stomach Neoplasms; Survival Rate; Tomography, Emission-Computed | 2004 |
Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy.
Topics: 3-Iodobenzylguanidine; Aged; Disease Progression; Endothelial Cells; Female; Humans; Lung; Male; Pulmonary Fibrosis; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Vascular Diseases | 2005 |
Survival of patients with neuroblastoma treated with 125-I MIBG.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Follow-Up Studies; Humans; Iodine Radioisotopes; Iodobenzenes; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Platelet Count; Remission Induction; Survival Rate; Treatment Outcome | 1996 |
32 other study(ies) available for 3-iodobenzylguanidine and Disease Exacerbation
| Article | Year |
|---|---|
Anatomic patterns of relapse and progression following treatment with
Topics: 3-Iodobenzylguanidine; Disease Progression; Humans; Iodine Radioisotopes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neuroblastoma; Retrospective Studies | 2022 |
Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Disease Progression; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2020 |
Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinson Disease; Vesicular Transport Proteins; Young Adult | 2021 |
Progression of myocardial sympathetic denervation assessed by
Topics: 3-Iodobenzylguanidine; Adult; Amyloid Neuropathies, Familial; Autonomic Nervous System Diseases; Cardiomyopathies; Disease Progression; Female; Humans; Liver Transplantation; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals | 2017 |
Cardiac Sympathetic Denervation Can Predict the Wearing-off Phenomenon in Patients with Parkinson Disease.
Topics: 3-Iodobenzylguanidine; Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Heart; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System | 2018 |
Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.
Topics: 3-Iodobenzylguanidine; Disease Progression; Female; Humans; Immunohistochemistry; Male; Molecular Imaging; Molecular Targeted Therapy; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Prevalence; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence | 2019 |
Dosimetry-based high-activity therapy with
Topics: 3-Iodobenzylguanidine; Adolescent; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Progression-Free Survival; Radiometry; Recurrence; Remission Induction; Retrospective Studies; Risk; Topotecan; Treatment Outcome; Young Adult | 2019 |
Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenal Glands; Adult; Aged; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hospitals, University; Humans; Hypertension; Iodine Radioisotopes; Japan; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Radionuclide Imaging; Radiopharmaceuticals; Registries | 2014 |
Prediction of adverse cardiac events in dilated cardiomyopathy using cardiac T2* MRI and MIBG scintigraphy.
Topics: 3-Iodobenzylguanidine; Adult; Area Under Curve; Cardiomyopathy, Dilated; Disease Progression; Disease-Free Survival; Female; Heart; Humans; Iron Deficiencies; Japan; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardium; Predictive Value of Tests; Radiopharmaceuticals; Risk Assessment; Risk Factors; ROC Curve; Sympathetic Nervous System; Tomography, Emission-Computed, Single-Photon | 2015 |
Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
Topics: 3-Iodobenzylguanidine; Adult; Antineoplastic Agents; Ascites; Bone Neoplasms; Disease Progression; Humans; Intestinal Neoplasms; Liver Neoplasms; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peritoneal Neoplasms; Radiopharmaceuticals | 2015 |
¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study.
Topics: 3-Iodobenzylguanidine; Aged; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Radionuclide Imaging; Radiopharmaceuticals; Regression Analysis; Risk Factors; ROC Curve; Time Factors; Ventricular Function, Left | 2015 |
Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infant; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroblastoma; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2015 |
Impact of renal sympathetic denervation on cardiac sympathetic nerve activity evaluated by cardiac MIBG imaging.
Topics: 3-Iodobenzylguanidine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Disease Progression; Drug Resistance; Echocardiography; Female; Heart; Heart Failure; Humans; Hypertension; Male; Middle Aged; Predictive Value of Tests; Radiopharmaceuticals; Renal Artery; Risk Factors; Sympathectomy; Sympathetic Nervous System; Treatment Outcome | 2016 |
[(123)I]-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson's disease: a case series study.
Topics: 3-Iodobenzylguanidine; Aged; Diagnosis, Differential; Disease Progression; Female; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Myocardial Perfusion Imaging; Nortropanes; Parkinson Disease; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2016 |
Clinical and histopathological features of progressive-type familial amyloidotic polyneuropathy with TTR Lys54.
Topics: 3-Iodobenzylguanidine; Adult; Amyloid Neuropathies, Familial; Autopsy; Disease Progression; Female; Glucose Tolerance Test; Humans; Lysine; Male; Mutation; Myocardial Perfusion Imaging; Peripheral Nerves; Prealbumin; Sural Nerve | 2009 |
Cardiac MIBG scintigraphy in Primary Progressive Freezing Gait.
Topics: 3-Iodobenzylguanidine; Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Female; Gait; Gait Apraxia; Heart; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals; Reference Values; Treatment Outcome | 2009 |
Differentiation of early-stage Alzheimer's disease from other types of dementia using brain perfusion single photon emission computed tomography with easy Z-score imaging system analysis.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cysteine; Dementia; Dementia, Vascular; Diagnosis, Differential; Disease Progression; Female; Humans; Image Processing, Computer-Assisted; Lewy Body Disease; Male; Middle Aged; Neuropsychological Tests; Organotechnetium Compounds; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2008 |
Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; Biomarkers, Tumor; Disease Progression; Female; Hormones; Humans; Male; Middle Aged; Neuroendocrine Tumors; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Pupillary autonomic dysfunction in multiple system atrophy and Parkinson's disease: an assessment by eye-drop tests.
Topics: 3-Iodobenzylguanidine; Aged; Autonomic Nervous System; Autonomic Nervous System Diseases; Blood Pressure; Disease Progression; Female; Heart Function Tests; Humans; Male; Middle Aged; Miotics; Multiple System Atrophy; Parkinson Disease; Pilocarpine; Pupil; Radionuclide Imaging; Radiopharmaceuticals; Reflex, Pupillary; ROC Curve | 2010 |
Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.
Topics: 3-Iodobenzylguanidine; Aged; Disease Progression; Female; Heart; Heart Failure; Humans; Iodine Radioisotopes; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Research Design; Risk Assessment; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left | 2010 |
Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients.
Topics: 3-Iodobenzylguanidine; Aged; Chi-Square Distribution; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Risk Assessment; Risk Factors; Stroke Volume; Sympathetic Nervous System; Time Factors; Ventricular Function, Left | 2011 |
Cardiac autonomic denervation in diabetes mellitus.
Topics: 3-Iodobenzylguanidine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Heart; Heart Failure; Humans; Predictive Value of Tests; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Risk Assessment; Risk Factors; Stroke Volume; Sympathetic Nervous System; Time Factors; Ventricular Function, Left | 2011 |
Camptocormia: as the first sign of Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Aged; Disease Progression; Female; Humans; Muscular Atrophy, Spinal; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Curvatures; Tropanes | 2011 |
Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Arrhythmias, Cardiac; Disease Progression; Female; Heart; Heart Failure; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Risk Assessment; Risk Factors; Stroke Volume; Sympathetic Nervous System; Time Factors; United States; Ventricular Function, Left | 2012 |
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Aged; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intracellular Signaling Peptides and Proteins; Iodine Isotopes; Male; Middle Aged; Oncogene Proteins; Parkinson Disease; Protein Deglycase DJ-1; Radionuclide Imaging | 2007 |
Decrease in myocardial 123I-MIBG radioactivity in REM sleep behavior disorder: two patients with different clinical progression.
Topics: 3-Iodobenzylguanidine; Age of Onset; Aged; Disease Progression; Electrocardiography; Follow-Up Studies; Heart; Humans; Lewy Body Disease; Male; Middle Aged; Myocardium; Parkinson Disease; Polysomnography; Radionuclide Imaging; REM Sleep Behavior Disorder; Sympathetic Fibers, Postganglionic | 2008 |
The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Pheochromocytoma; Positron-Emission Tomography; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2008 |
Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Child, Preschool; Cisplatin; Combined Modality Therapy; Disease Progression; Hematologic Diseases; Hemorrhage; Humans; Infant; Infections; Iodine Radioisotopes; Iodobenzenes; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Prognosis; Radiation-Sensitizing Agents; Radiopharmaceuticals; Remission Induction | 1995 |
Sympathetic denervation of myocardium demonstrated by 123I-MIBG scintigraphy in pure progressive autonomic failure.
Topics: 3-Iodobenzylguanidine; Autonomic Nervous System Diseases; Disease Progression; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Radiopharmaceuticals; Sympathectomy; Tomography, Emission-Computed, Single-Photon | 1997 |
Decreased myocardial 123I-MIBG uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Aged; Case-Control Studies; Disease Progression; Female; Heart; Humans; Iodine Radioisotopes; Male; Mediastinum; Middle Aged; Myocardium; Parkinson Disease; Sympathetic Nervous System; Sympatholytics; Tomography, Emission-Computed, Single-Photon | 1998 |
[An autopsy case of multiple system atrophy presenting with rapid progression of autonomic disturbance].
Topics: 3-Iodobenzylguanidine; Autonomic Nervous System Diseases; Brain; Disease Progression; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Multiple System Atrophy; Olivopontocerebellar Atrophies; Radionuclide Imaging; Radiopharmaceuticals | 1999 |
Relationship between cardiac metaiodobenzylguanidine uptake and hemodynamic, functional and neurohormonal parameters in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Chronic Disease; Disease Progression; Exercise Test; Female; Heart; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Neurotransmitter Agents; Norepinephrine; Oxygen Consumption; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume | 2001 |